Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial-Reference-Cited by-同舟云学术

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

Published:2022-02-25 Issue:1 Volume:193 Page:95-103
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Campone Mario^ORCID,De Laurentiis Michelino,Zamagni Claudio,Kudryavcev Igor,Agterof Mariëtte,Brown-Glaberman Ursa,Palácová Markéta,Chatterjee Sanjoy,Menon-Singh Lakshmi,Wu Jiwen,Martín Miguel

Funder

Novartis Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06543-1.pdf

Reference35 articles.

1. American Cancer Society About breast cancer in men (2018) https://www.cancer.org/content/dam/CRC/PDF/Public/8587.00.pdf. Accessed 5 Jan 2022

2. Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, Zheng Y, Zhai Z, Hao Q, Song D, Zhang D, Kang H, Dai Z (2019) Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017. J Hematol Oncol 12:140. https://doi.org/10.1186/s13045-019-0828-0

3. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442